[Immunosuppression by means of antilymphocyte serums in humans].
D000818:Animals; D000906:Antibodies; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000494:pharmacology*; D001327:Autoimmune Diseases / Q000188:drug therapy; D003601:Cytotoxicity Tests, Immunologic; D006084:Graft Rejection / Q000187:drug effects; D000882:Haplorhini; D006801:Humans; D006968:Hypersensitivity, Delayed; D007158:Immunologic Techniques; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007167:Immunotherapy; D066298:In Vitro Techniques; D016030:Kidney Transplantation; D008213:Lymphocyte Activation; D008212:Lymphocyte Depletion; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
D000906:Antibodies; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents
Immunosuppression par les sérums antilymphocytaires dans l'espèce humaine.